Bristol-Myers Squibb Company (BMY) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Bristol-Myers Squibb financial statements at a glance

Bristol-Myers Squibb reported revenue of $48.20 billion for fiscal year 2025 (ended December 31, 2025), down 0.2% from fiscal year 2024. Net income was $7.05 billion, a net margin of 14.6%, and diluted earnings per share were $3.46.

At the end of fiscal year 2025 it had total assets of $90.04 billion, total liabilities of $71.53 billion and shareholders' equity of $18.47 billion, with cash and short-term investments of $10.67 billion and total debt of $47.14 billion.

Its operations brought in $14.16 billion of cash; capital spending was $1.31 billion, leaving free cash flow of $12.85 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

BMY logo

Bristol-Myers Squibb Company

BMYUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
48.20B
Prev Year: 48.30B
YoY: -0.2%
Operating Revenue
47.20B
Prev Year: 47.26B
YoY: -0.1%
Total Unusual Items
-4.71B
Prev Year: -12.89B
YoY: +63.4%
Normalized EBITDA
19.95B
Prev Year: 16.06B
YoY: +24.2%
Tax Rate for Calcs
0.244
Prev Year: 0
Tax Effect of Unusual Items
-1.15B
Prev Year: -2.71B
YoY: +57.6%
Noncontrolling Interests
-2.00M
Prev Year: -15.00M
YoY: +86.7%
Depreciation Amortization Depletion
3.32B
Prev Year: 8.87B
YoY: -62.6%
Depreciation and amortization
3.32B
Prev Year: 8.87B
YoY: -62.6%
Amortization
3.32B
Prev Year: 8.87B
YoY: -62.6%
Amortization of Intangibles
3.32B
Prev Year: 8.87B
YoY: -62.6%
Cost of Revenue
13.94B
Prev Year: 13.97B
YoY: -0.2%
Gross Profit
34.26B
Prev Year: 34.33B
YoY: -0.2%
Operating Expense
20.54B
Prev Year: 28.45B
YoY: -27.8%
Selling General and Administrative
7.27B
Prev Year: 8.41B
YoY: -13.6%
Research and Development
9.95B
Prev Year: 11.16B
YoY: -10.8%
Operating Income
13.72B
Prev Year: 5.89B
YoY: +133.1%
Net Non Operating Interest Income Expense
-1.89B
Prev Year: -1.95B
YoY: +2.9%
Non-operating Interest Expense
1.89B
Prev Year: 1.95B
YoY: -2.9%
Other Income Expense
-2.50B
Prev Year: -12.32B
YoY: +79.7%
Gain on Sale of Securities
510.00M
Prev Year: 494.00M
YoY: +3.2%
Special Income Charges
-5.22B
Prev Year: -13.38B
YoY: +61.0%
Equity in Earnings of Affiliates
-
Restructuring and Mergers Acquisition
4.79B
Prev Year: 14.34B
YoY: -66.6%
Other Special Charges
434.00M
Prev Year: 84.00M
YoY: +416.7%
Impairment of Capital Assets
-
Prev Year: 47.00M
Other Non-operating Income (expense)
2.21B
Prev Year: 571.00M
YoY: +287.2%
Pre-tax Income
9.33B
Prev Year: -8.38B
YoY: +211.3%
Provision for Income Taxes
2.27B
Prev Year: 554.00M
YoY: +310.1%
Net Income Common Stockholders
7.05B
Prev Year: -8.95B
YoY: +178.8%
Net Income
7.05B
Prev Year: -8.95B
YoY: +178.8%
Net Income Including Non-Controlling Interests
7.05B
Prev Year: -8.93B
YoY: +179.0%
Net Income from Continuing Operations
7.05B
Prev Year: -8.93B
YoY: +179.0%
Diluted NI Available to Com Stockholders
7.05B
Prev Year: -8.95B
YoY: +178.8%
Basic EPS
3.47
Prev Year: -4.41
YoY: +178.7%
Diluted EPS
3.46
Prev Year: -4.41
YoY: +178.5%
Weighted Average Shares (basic)
2.03B
Prev Year: 2.03B
YoY: +0.3%
Weighted Average Shares (diluted)
2.04B
Prev Year: 2.03B
YoY: +0.6%
Total Expenses
34.47B
Prev Year: 42.41B
YoY: -18.7%
Net Income from Continuing and Discontinued Operation
7.05B
Prev Year: -8.95B
YoY: +178.8%
Normalized Income
10.62B
Prev Year: 1.24B
YoY: +759.9%
Interest Expense
1.89B
Prev Year: 1.95B
YoY: -2.9%
Net Interest Income
-1.89B
Prev Year: -1.95B
YoY: +2.9%
EBIT
11.22B
Prev Year: -6.43B
YoY: +274.4%
EBITDA
15.23B
Prev Year: 3.17B
YoY: +380.7%
Reconciled Cost of Revenue
13.24B
Prev Year: 13.24B
YoY: +0.0%
Reconciled Depreciation
4.01B
Prev Year: 9.60B
YoY: -58.2%
Net Income from Continuing Operation Net Minority Interest
7.05B
Prev Year: -8.95B
YoY: +178.8%
Total Unusual Items Excluding Goodwill
-4.71B
Prev Year: -12.89B
YoY: +63.4%
Values in USD

Bristol-Myers Squibb key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$48.2B$48.3B$45.0B$46.2B$46.4B
Gross profit$34.3B$34.3B$34.3B$36.0B$36.4B
Operating income$13.7B$5.9B$8.2B$9.1B$8.5B
Net income$7.1B-$8.9B$8.0B$6.3B$7.0B
Diluted EPS$3.46-$4.41$3.86$2.95$3.12
Total assets$90.0B$92.6B$95.2B$96.8B$109.3B
Total liabilities$71.5B$76.2B$65.7B$65.7B$73.3B
Shareholders' equity$18.5B$16.3B$29.4B$31.1B$35.9B
Cash and short-term investments$10.7B$10.9B$12.3B$9.3B$17.2B
Total debt$47.1B$51.2B$41.5B$40.7B$45.6B
Operating cash flow$14.2B$15.2B$13.9B$13.1B$16.2B
Capital spending$1.3B$1.2B$1.2B$1.1B$973.0M
Free cash flow$12.8B$13.9B$12.7B$11.9B$15.2B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Bristol-Myers Squibb's revenue in fiscal year 2025?

$48.20 billion, down 0.2% from $48.30 billion in fiscal year 2024.

How much profit does Bristol-Myers Squibb make?

Bristol-Myers Squibb reported net income of $7.05 billion for fiscal year 2025 (14.6% of revenue); operating income was $13.72 billion.

How much cash and debt does Bristol-Myers Squibb have?

At the end of fiscal year 2025: cash and short-term investments of $10.67 billion and total debt of $47.14 billion.

What is Bristol-Myers Squibb's free cash flow?

$12.85 billion in fiscal year 2025 (operating cash flow of $14.16 billion minus capital spending of $1.31 billion).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube